Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Niraparib. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN119698468A details engineered transaminases for niraparib synthesis, offering high stereoselectivity and scalable biocatalytic solutions for pharmaceutical supply chains.
Patent CN107311911B reveals a novel chemical route for Niraparib intermediates, replacing costly enzymatic methods with scalable asymmetric synthesis for reliable supply.
Novel non-enzymatic synthesis of niraparib intermediate via oxazolone route. High purity, scalable process offering significant cost reduction in API manufacturing.
Patent CN116179503A details a novel recombinant aminotransferase route for Niraparib intermediates, offering high stereoselectivity and eliminating costly chiral chromatography for supply chain efficiency.
Novel copper-catalyzed route for (S)-3-(4-bromophenyl)piperidine avoids azides and enzymes, offering cost-effective pharma intermediate manufacturing.
Novel Ru-catalyzed asymmetric hydrogenation route for Niraparib intermediate. High yield, scalable process for pharmaceutical supply chains.
Patent CN109134351B details a novel synthesis of S-3-(4-aminophenyl)piperidine with >99% ee, offering cost-effective scalability for PARP inhibitor manufacturing.
Patent CN115611860A discloses a safe, high-yield Niraparib synthesis avoiding sodium azide. Ideal for cost reduction in API manufacturing and supply chain stability.
Overcome chiral resolution challenges in Niraparib manufacturing. New metal-free synthesis achieves 97.51% purity with 26.75% overall yield. Reduce equipment costs and supply chain risks.